ARCTArcturus Therapeutics Holdings Inc.
Pharmaceutical Preparations
- Revenue
- $82M
- 46% YoY
- Operating margin
- -93.0%
- 48% YoY
- EBITDA
- −$73M
- 21% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$178M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired31% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $12M | $206M | $167M | $152M | $82M | 46% |
| Operating income | −$203M | $12M | −$78M | −$96M | −$76M | 20% |
| Net income | −$204M | $9M | −$30M | −$81M | −$66M | 19% |
| Operating cash flow | −$135M | $32M | −$18M | −$60M | −$74M | 24% |
| Capex | $3M | $8M | $3M | $648K | $230K | 65% |
| Stock-based comp | $29M | $31M | $35M | $38M | $25M | 33% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.